Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3%, currently at 3.25 HKD, following the announcement of the successful administration of the first patient in a multi-dose escalation (MAD) Phase Ib trial for HMS1005, a second-generation glucose kinase activator [1][2]. Group 1: Clinical Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) subjects in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1]. Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow for once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1]. - The drug aims to improve the repair capacity of patients with insufficient GLP-1 secretion [1]. Group 3: Future Plans - Following the successful completion of the MAD Ib study, the company plans to seek partners for the global development of HMS1005 [2].

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3% following the successful administration of the first patient in the MAD Ib trial of its second-generation glucose kinase activator (GKA), HMS1005, in the United States [1][2] Group 1: Trial Details - The MAD Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) patients in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1] Group 2: Drug Characteristics - HMS1005 is a new molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and increasing the duration of the drug's action in the intestine [2] - The company has previously completed and published results from a single-dose escalation study of HMS1005, confirming its feasibility for once-daily oral treatment in T2D and obesity patients [2] Group 3: Future Plans - Following the successful completion of the MAD Ib trial, the company plans to seek partners for the global development of HMS1005 [2]

Core Viewpoint - The company has initiated a multi-dose escalation Phase Ib trial for its second-generation glucose kinase activator (GKA), HMS1005, in the United States, marking a significant step in its development for treating type 2 diabetes (T2D) [1] Group 1: Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in T2D subjects [1] - The study will evaluate pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon in both fasting and fed states, alongside continuous glucose monitoring (CGM) to explore the mechanism and effects of HMS1005 [1] Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1] - The drug aims to improve the repair of GLP-1 secretion deficiencies in patients [1] Group 3: Future Plans - Upon successful completion of the MAD Phase Ib study, the company plans to seek partnerships for the global development of HMS1005 [1]